Cargando…
Dasatinib-induced spleen contraction leads to transient lymphocytosis
The tyrosine kinase inhibitor dasatinib is approved for Philadelphia chromosome–positive leukemia, including chronic myeloid leukemia (CML). Although effective and well tolerated, patients typically exhibit a transient lymphocytosis after dasatinib uptake. To date, the underlying physiological proce...
Autores principales: | Marcos-Jiménez, Ana, Carvoeiro, Daniela Claudino, Ruef, Nora, Cuesta-Mateos, Carlos, Roy-Vallejo, Emilia, Gómez-García de Soria, Valle, Laganá, Claudio, del Campo, Lourdes, Zubiaur, Pablo, Villapalos-García, Gonzalo, Abad-Santos, Francisco, Stein, Jens V., Muñoz-Calleja, Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238846/ https://www.ncbi.nlm.nih.gov/pubmed/36583674 http://dx.doi.org/10.1182/bloodadvances.2022009279 |
Ejemplares similares
-
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
por: Mouhieddine, Tarek H., et al.
Publicado: (2022) -
TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
por: Shaw, Lauren C., et al.
Publicado: (2022) -
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
por: Botta, Cirino, et al.
Publicado: (2022) -
CD34(+)CD19(−)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
por: Bueno, Clara, et al.
Publicado: (2022) -
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)